Piramal Healthcare, country’s largest drug maker is likely to invest Rs 200 crore on various research and development activities this fiscal, including clinical trials for its two cancer molecules. It is currently conducting Phase I clinical trials for its tumour suppressor treatment molecule 'P1446A- 05' and blood cell cancer treatment molecule 'P2745'.
The company is also working on an investigational new drug (IND) application for conducting Phase I clinical studies of a molecule code named 'P7170'. The trial results of the molecules are being presented at the annual general meeting of the American Association for Cancer Research (AACR) being held at Chicago.
Piramal Healthcare, formerly known as Nicholas Piramal, is one of the largest pharmaceutical companies in India. Being part of Piramal Group, its healthcare division contributes 50% to group’s revenue. Besides healthcare, the Piramal Group has business interests in areas of glass manufacturing, retail and real estate.
| Company Name | CMP |
|---|---|
| Bajaj Finance | 959.10 |
| Shriram Finance | 1002.90 |
| Aditya Birla Capital | 370.45 |
| Chola Invest & Fin. | 1689.10 |
| Tata Capital | 344.65 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: